Novo Nordisk reported DKK13.22B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Bausch Health Companies USD 813M 12M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 83.88M 7.99M Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026